Skip to main content

Orthocell seeks FDA nod

19/12/2024 - 11:37

Bookmark

Save articles for future reference.

Orthocell has submitted its application for US Food and Drug Administration approval for its Remplir nerve regeneration product, marking another moment in a year full of milestones.

X

To read our articles you will need to either login or subscribe.